The Development of Combination Therapies for HIV Infection

Palella FJ Jr , Delaney KM , Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med., 1998; 338,13:853–860.

Mocroft A , Ledergerber B , Katlama C et al. EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 2003; 362,9377:22–29.

Hogg RS , Heath KV , Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA, 1998; 279,6:450–454.

Barre-Sinoussi F , Chermann JC , Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science, 1983; 220,4599:868–871.

Popovic M , Sarngadharan MG , Read E et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science, 1984; 224,4648:497–500.

Gallo RC , Salahuddin SZ , Popovic M et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 1984; 224,4648:500–503.

Schüpbach J , Popovic M , Gilden RV et al. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science, 1984; 224,4648:503–505.

Sarngadharan MG , Popovic M , Bruch L et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science, 1984; 224,4648:506–508.

Safai B , Sarngadharan MG , Groopman JE et al. Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet, 1984; 1,8392:1438–1440.

Gazzard BG , Shanson DC , Farthing C et al. Clinical findings and serological evidence of HTLV-III infection in homosexual contacts of patients with AIDS and persistent generalised lymphadenopathy in London. Lancet, 1984; 2,8401:480–483.

Levy JA , Hoffman AD , Kramer SM et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science, 1984; 225,4664:840–842.

Centers for Disease Control (CDC). Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR Morb Mortal Wkly Rep, 1984; 33,27:377–379.

Temin HM , Mizutani S . RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature, 1970; 226,5252:1211–1213.

Baltimore D . RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature, 1970; 226,5252:1209–1201.

De Clercq E , Billiau A , Hobbs J et al. Inhibition of oncornavirus functions by 2'-azido polynucleotides. Proc Natl Acad Sci U S A, 1975; 72,1:284–288.

Green M , Bragdon J , Rankin A . 3-Cyclic amine derivatives of rifamycin: strong inhibitors of the DNA polymerase activity of RNA tumor viruses. Proc Natl Acad Sci U S A, 1972; 69,5:1294–1298.

Gurgo C , Ray R , Green M . Rifamycin derivatives strongly inhibiting RNA leads to DNA polymerase (reverse transcriptase) of murine sarcoma viruses. J Natl Cancer Inst, 1972; 49,1:61–79.

Chandra P , Kornhuber B , Gericke D et al. Inhibition of viral reverse transcriptase and leukemogenesis by modified nucleic acids. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol, 1975; 83,3:239–49.

Yang SS , Herrera FM , Smith RG et al. Rifamycin antibiotics: inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts. J Natl Cancer Inst, 1972; 49,1:7–25.

Mitsuya H , Weinhold KJ , Furman PA et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A, 1985; 82,20:7096–7100.

Fischl MA , Richman DD , Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med, 1987; 317,4:185–191.

Larder BA , Darby G , Richman DD . HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science, 1989; 243,4899:1731–1734.

Volberding PA , Lagakos SW , Koch MA et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter: The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med, 1990; 322,14:941–949.

Collier AC , Bozzette S , Coombs RW et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med, 1990; 323,15:1015–1021.

Fischl MA , Parker CB , Pettinelli C et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome: The AIDS Clinical Trials Group. N Engl J Med, 1990; 323,15:1009–1014.

Nordic Medical Research Councils' HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ, 1992; 304,6818:13–17.

Lambert JS , Seidlin M , Reichman RC et al. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N Engl J Med, 1990; 322,19:1333–1340.

Cooley TP , Kunches LM , Saunders CA et al. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a Phase I trial. N Engl J Med, 1990; 322,19:1340–1345.

Yarchoan R , Mitsuya H , Pluda JM et al. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis, 1990; 12,Suppl 5:S522–S533.

Yarchoan R , Perno CF , Thomas RV et al. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT) Lancet, 1988; 1,8577:76–81.

Merigan TC , Skowron G , Bozzette SA et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med, 1989; 110,3:189–194.

Hammer SM , Katzenstein DA , Hughes MD et al. trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter: AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med, 1996; 335,15:1081–1090.

Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet, 1996; 348,9023:283–291.

Eron JJ , Benoit SL , Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter: North American HIV Working Party. N Engl J Med, 1995; 333,25:1662–1669.

Bartlett JA , Benoit SL , Johnson VA et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med, 1996; 125,3:161–172.

Katlama C , Ingrand D , Loveday C et al. Efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy: Lamivudine European HIV Working Group. JAMA, 1996; 276,2:118–125.

Staszewski S , Loveday C , Picazo JJ et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy: Lamivudine European HIV Working Group. JAMA, 1996; 276,2:111–117.

Schrey G . The HIV Trial Guide: A Guide to Major Studies, Trials and Acronyms of HIV Antiretroviral Therapy 1985–2004, 3 ^rd. Alphen a/d Rijn, The Netherlands: Van Zuiden Communications B.V., 2004; 92–120.

D'Aquila RT , Hughes MD , Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med, 1996; 124,12:1019–1030.

Montaner JS , Reiss P , Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA, 1998; 279,12:930–937.

Friedland GH , Pollard R , Griffith B et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261) ACTG 261 Team. J Acquir Immune Defic Syndr, 1999; 21,4:281–292.

Staszewski S , Morales-Ramirez J , Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: Study 006 Team. N Engl J Med, 1999; 341,25:1865–1873.

Chow YK , Hirsch MS , Merrill DP et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature, 1993; 361,6413:650–654.

Chow YK , Hirsch MS , Kaplan JC et al. HIV-1 error revealed. Nature, 1993; 364,6439:679.

Larder BA , Kellam P , Kemp SD . Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature, 1993; 365,6445:451–453.

Emini EA , Graham DJ , Gotlib L et al. HIV and multidrug resistance. Nature, 1993; 364,6439:679.

Soo W , Nauss-Karol C , Elkins M et al. Inter-Company Collaboration Combination Trials: Clinical Trial Subcommittee of the Inter-Company Collaboration for AIDS Drug Development. J Acquir Immune Defic Syndr Hum Retrovirol, 1995; 10,Suppl 2:S92–S96.

Copeland TD , Oroszlan S . Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. Gene Anal Tech, 1988; 5,6:109–115.

Navia MA , Fitzgerald PM , McKeever BM et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature, 1989; 337,6208:615–620.

Haubrich R , Lalezari J , Follansbee E et al. and the NV14256 Study Team. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther, 1998; 3:33–42.

Collier AC , Coombs RW , Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine; AIDS Clinical Trials Group. N Engl J Med, 1996; 334,16:1011–1017.

Schapiro JM , Winters MA , Stewart F et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med, 1996; 124,12:1039–1050.

Vella S , Lazzarin A , Carosi G et al. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antivir Ther, 1996; 1,3:129–140.

Collier AC , Coombs RW , Schoenfeld DA et al. Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res, 1996; 29,1:99.

Stein DS , Fish DG , Bilello JA et al. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir) AIDS, 1996; 10,5:485–492.

Condra JH , Schleif WA , Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature, 1995; 374,6522:569–571.

Gulick RM , Mellors JW , Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med, 1997; 337,11:734–739.

Hammer SM , Squires KE , Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team. N Engl J Med, 1997; 337,11:725–733.

Hirsch M , Steigbigel R , Staszewski S et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis, 1999; 180,3:659–665.

AVANTI 2: Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS, 2000; 14,4:367–374.

García F , Alonso MM , Romeu J et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study, Early Anti-Retroviral Therapy Study. J Acquir Immune Defic Syndr, 2000; 25,1:26–35.

Danner SA , Carr A , Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease: European-Australian Collaborative Ritonavir Study Group. N Engl J Med, 1995; 333,23:1528–1533.

Markowitz M , Saag M , Powderly WG et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med, 1995; 333,23:1534–1539.

Cameron DW , Heath-Chiozzi M , Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease: The Advanced HIV Disease Ritonavir Study Group. Lancet, 1998; 351,9102:543–549.

Mathez D , Bagnarelli P , Gorin I et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antivir Ther, 1997; 2,3:175–183.

Mellors JW , Rinaldo CR Jr , Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 1996; 272,5265:1167–1170.

Mathez D , Paul D , de Bélilovsky C et al. Productive human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient. Proc Natl Acad Sci U S A, 1990; 87,19:7438–7442.

Wei X , Ghosh SK , Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 1995; 373,6510:117–122.

Ho DD , Neumann AU , Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995; 373,6510:123–126.

Perelson AS , Neumann AU , Markowitz M et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 1996; 271,5255:1582–1586.

Herz AV , Bonhoeffer S , Anderson RM et al. Dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci U S A, 1996; 93,14:7247–7251.

Pantaleo G , Graziosi C , Demarest JF et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature, 1993; 362,6418:355–358.

Embretson J , Zupancic M , Ribas JL et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature, 1993; 362,6418:359–362.

Grossman Z , Paul WE . The impact of HIV on naïve T-cell homeostasis. Nat Med, 2000; 6,9:976–977.

Hazenberg MD , Hamann D , Schuitemaker H et al. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol, 2000; 1,4:285–289.

McCune JM . The dynamics of CD4+ T-cell depletion in HIV disease. Nature, 2001; 410,6831:974–979.

Sedaghat AR , Siliciano JD , Brennan TP et al. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog, 2007; 3,8:e122.

Ho DD . Time to hit HIV, early and hard. N Engl J Med, 1995; 333,7:450–451.

Finzi D , Blankson J , Siliciano JD et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med, 1999; 5,5:512–517.

Chun TW , Stuyver L , Mizell SB et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A, 1997; 94,24:13193–13197.

Chun TW , Fauci AS . Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A, 1999; 96,20:10958–10961.

Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, February 5 2001; 1–108. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Yeni PG , Hammer SM , Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA, 2002; 288,2:222–235.

BHIVA Writing Committee; BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med, 2000; 1,2:76–101.